S&P 500   3,136.63 (+0.02%)
DOW   27,903.39 (-0.02%)
QQQ   204.45 (+0.19%)
AAPL   269.43 (+0.94%)
FB   200.99 (-0.17%)
MSFT   151.54 (+0.12%)
GOOGL   1,345.01 (+0.15%)
AMZN   1,741.09 (-0.48%)
NVDA   215.00 (+1.33%)
MU   47.70 (+2.67%)
BABA   201.29 (+1.28%)
GE   11.00 (+0.00%)
TSLA   349.81 (+3.03%)
T   38.20 (+0.42%)
AMD   39.69 (+1.95%)
F   9.09 (+0.89%)
PRI   135.36 (+0.00%)
NFLX   297.53 (-1.64%)
BAC   33.49 (-0.06%)
GILD   66.96 (+0.04%)
S&P 500   3,136.63 (+0.02%)
DOW   27,903.39 (-0.02%)
QQQ   204.45 (+0.19%)
AAPL   269.43 (+0.94%)
FB   200.99 (-0.17%)
MSFT   151.54 (+0.12%)
GOOGL   1,345.01 (+0.15%)
AMZN   1,741.09 (-0.48%)
NVDA   215.00 (+1.33%)
MU   47.70 (+2.67%)
BABA   201.29 (+1.28%)
GE   11.00 (+0.00%)
TSLA   349.81 (+3.03%)
T   38.20 (+0.42%)
AMD   39.69 (+1.95%)
F   9.09 (+0.89%)
PRI   135.36 (+0.00%)
NFLX   297.53 (-1.64%)
BAC   33.49 (-0.06%)
GILD   66.96 (+0.04%)
S&P 500   3,136.63 (+0.02%)
DOW   27,903.39 (-0.02%)
QQQ   204.45 (+0.19%)
AAPL   269.43 (+0.94%)
FB   200.99 (-0.17%)
MSFT   151.54 (+0.12%)
GOOGL   1,345.01 (+0.15%)
AMZN   1,741.09 (-0.48%)
NVDA   215.00 (+1.33%)
MU   47.70 (+2.67%)
BABA   201.29 (+1.28%)
GE   11.00 (+0.00%)
TSLA   349.81 (+3.03%)
T   38.20 (+0.42%)
AMD   39.69 (+1.95%)
F   9.09 (+0.89%)
PRI   135.36 (+0.00%)
NFLX   297.53 (-1.64%)
BAC   33.49 (-0.06%)
GILD   66.96 (+0.04%)
S&P 500   3,136.63 (+0.02%)
DOW   27,903.39 (-0.02%)
QQQ   204.45 (+0.19%)
AAPL   269.43 (+0.94%)
FB   200.99 (-0.17%)
MSFT   151.54 (+0.12%)
GOOGL   1,345.01 (+0.15%)
AMZN   1,741.09 (-0.48%)
NVDA   215.00 (+1.33%)
MU   47.70 (+2.67%)
BABA   201.29 (+1.28%)
GE   11.00 (+0.00%)
TSLA   349.81 (+3.03%)
T   38.20 (+0.42%)
AMD   39.69 (+1.95%)
F   9.09 (+0.89%)
PRI   135.36 (+0.00%)
NFLX   297.53 (-1.64%)
BAC   33.49 (-0.06%)
GILD   66.96 (+0.04%)
Log in

NASDAQ:CRNX - Crinetics Pharmaceuticals Stock Price, Forecast & News

$20.75
+0.41 (+2.02 %)
(As of 12/10/2019 01:13 PM ET)
Today's Range
$19.79
Now: $20.75
$20.84
50-Day Range
$16.40
MA: $18.64
$20.63
52-Week Range
$14.33
Now: $20.75
$35.70
Volume77,716 shs
Average Volume45,687 shs
Market Capitalization$502.57 million
P/E RatioN/A
Dividend YieldN/A
Beta0.95
Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRNX
CUSIPN/A
CIKN/A
Phone858-450-6464

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.43 million
Book Value$6.67 per share

Profitability

Net Income$-27,110,000.00
Net Margins-1,303.31%

Miscellaneous

Employees47
Market Cap$502.57 million
Next Earnings Date3/11/2020 (Estimated)
OptionableNot Optionable

Receive CRNX News and Ratings via Email

Sign-up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter.


Crinetics Pharmaceuticals (NASDAQ:CRNX) Frequently Asked Questions

What is Crinetics Pharmaceuticals' stock symbol?

Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."

How were Crinetics Pharmaceuticals' earnings last quarter?

Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.57) by $0.03. The company had revenue of $0.51 million for the quarter, compared to analysts' expectations of $0.33 million. Crinetics Pharmaceuticals had a negative net margin of 1,303.31% and a negative return on equity of 30.38%. View Crinetics Pharmaceuticals' Earnings History.

When is Crinetics Pharmaceuticals' next earnings date?

Crinetics Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Crinetics Pharmaceuticals.

What price target have analysts set for CRNX?

2 analysts have issued 1 year price objectives for Crinetics Pharmaceuticals' stock. Their forecasts range from $35.00 to $40.00. On average, they anticipate Crinetics Pharmaceuticals' share price to reach $37.50 in the next twelve months. This suggests a possible upside of 81.2% from the stock's current price. View Analyst Price Targets for Crinetics Pharmaceuticals.

What is the consensus analysts' recommendation for Crinetics Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Crinetics Pharmaceuticals.

What are Wall Street analysts saying about Crinetics Pharmaceuticals stock?

Here are some recent quotes from research analysts about Crinetics Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Crinetics Pharmaceuticals Inc is a clinical stage pharmaceutical company. It focuses on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's product pipeline consists of CRN00808 for the treatment of Acromegaly, CRN02481 for the treatment of Hyperinsulinemias and CRN01941 for the treatment of Neuroendocrine Tumors which are in clinical stage. Crinetics Pharmaceuticals Inc is based in San Diego, United States. " (10/15/2019)
  • 2. HC Wainwright analysts commented, "Valuation; reiterate Buy rating. Our $35 price target for Crinets is based on our sum-of-the-parts NPV valuation based on each of the company’s ongoing products. Our DCF model utilizes a discount rate of 12.2% based on the company’s WACC (Beta of 1.1, equity risk premium of 6.7%)." (4/16/2019)

Has Crinetics Pharmaceuticals been receiving favorable news coverage?

News coverage about CRNX stock has been trending somewhat positive on Tuesday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Crinetics Pharmaceuticals earned a coverage optimism score of 1.2 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Crinetics Pharmaceuticals.

Who are some of Crinetics Pharmaceuticals' key competitors?

What other stocks do shareholders of Crinetics Pharmaceuticals own?

Who are Crinetics Pharmaceuticals' key executives?

Crinetics Pharmaceuticals' management team includes the folowing people:
  • Dr. R. Scott Struthers, Founder, Pres, CEO & Director (Age 57)
  • Mr. Marc J. C. Wilson, CFO & Sec. (Age 40)
  • Dr. Alan S. Krasner, Chief Medical Officer (Age 56)
  • Dr. Stephen F. Betz, Co-Founder & VP of Biology (Age 53)

When did Crinetics Pharmaceuticals IPO?

(CRNX) raised $80 million in an IPO on Wednesday, July 18th 2018. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray acted as the underwriters for the IPO.

Who are Crinetics Pharmaceuticals' major shareholders?

Crinetics Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Eventide Asset Management LLC (3.91%), State Street Corp (0.85%), Point72 Asset Management L.P. (0.55%), Millennium Management LLC (0.23%), Alps Advisors Inc. (0.20%) and Barclays PLC (0.02%). Company insiders that own Crinetics Pharmaceuticals stock include Alan Seth Krasner, Life Sciences Maste Perceptive, Ventures Iv LP 5Am, Vivo Capital Fund Viii, LP and Vivo Capital Viii, Llc. View Institutional Ownership Trends for Crinetics Pharmaceuticals.

Which institutional investors are selling Crinetics Pharmaceuticals stock?

CRNX stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC and Alps Advisors Inc.. Company insiders that have sold Crinetics Pharmaceuticals company stock in the last year include Ventures Iv LP 5Am and Vivo Capital Fund Viii, LP. View Insider Buying and Selling for Crinetics Pharmaceuticals.

Which institutional investors are buying Crinetics Pharmaceuticals stock?

CRNX stock was bought by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Point72 Asset Management L.P., Millennium Management LLC, State Street Corp and Tower Research Capital LLC TRC. Company insiders that have bought Crinetics Pharmaceuticals stock in the last two years include Alan Seth Krasner, Life Sciences Maste Perceptive and Vivo Capital Viii, Llc. View Insider Buying and Selling for Crinetics Pharmaceuticals.

How do I buy shares of Crinetics Pharmaceuticals?

Shares of CRNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Crinetics Pharmaceuticals' stock price today?

One share of CRNX stock can currently be purchased for approximately $20.70.

How big of a company is Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals has a market capitalization of $501.35 million and generates $2.43 million in revenue each year. The company earns $-27,110,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis. Crinetics Pharmaceuticals employs 47 workers across the globe.View Additional Information About Crinetics Pharmaceuticals.

What is Crinetics Pharmaceuticals' official website?

The official website for Crinetics Pharmaceuticals is http://www.crinetics.com/.

How can I contact Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The company can be reached via phone at 858-450-6464 or via email at [email protected]


MarketBeat Community Rating for Crinetics Pharmaceuticals (NASDAQ CRNX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  65 (Vote Outperform)
Underperform Votes:  75 (Vote Underperform)
Total Votes:  140
MarketBeat's community ratings are surveys of what our community members think about Crinetics Pharmaceuticals and other stocks. Vote "Outperform" if you believe CRNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2019 by MarketBeat.com Staff

Featured Article: Support Level

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel